These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35988929)

  • 1. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
    Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
    Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
    BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
    Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
    Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
    Zhou Y; Xu M; Zhao K; Liu B
    J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis.
    Zhou Y; Guo Y; Wang Y
    IET Syst Biol; 2022 Apr; 16(2):72-83. PubMed ID: 35352485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.